In the wave of high-quality development in the pharmaceutical industry,Pharmaceutical excipientsQuality and innovation have become key factors driving drug development and production. Recently, a biopharmaceutical company in JiangsuNanjing Chemical Reagent Co., LtdStrategic cooperation will be reached, and both parties will focus onAnhydrous ethanol pharmaceutical excipientDeepen cooperation in the field, jointly create high-quality and high standard pharmaceutical excipient solutions, and inject new momentum into the pharmaceutical industry.
Based on quality, jointly build a safety defense line
absolute ethanolAs a pharmaceutical excipient, it plays an irreplaceable role in drug production, disinfection, solvents, and other fields. Its purity, impurity control, and stability directly affect the quality and safety of drugs. Both parties will jointly establish a full process quality control system from raw material screening to finished product inspection, ensuring that anhydrous ethanol pharmaceutical excipients comply with national pharmacopoeia standards and safeguard drug safety.
Driven by innovation, industry transformation
Faced with the continuous upgrading of functional and personalized demands for excipients in the pharmaceutical industry, both parties have jointly carried out technological research and development to promote the innovation and upgrading of anhydrous ethanol pharmaceutical excipients. By optimizing production processes and developing new application scenarios, such as special solvent requirements for biologics and efficient formulations for disinfectants, both parties are committed to creating a more competitive product matrix to meet the diverse needs of clinical medication and public health. This cooperation is not only the integration of resources, but also the deep integration of technology, concepts, and market insights.
Using cooperation as a bridge to empower industrial ecology
This cooperation is not only a win-win situation for both companies, but also a positive empowerment of the pharmaceutical industry chain ecology. Through resource sharing and complementary advantages, both parties are expected to form a complete closed loop from research and development to application, providing pharmaceutical companies with more efficient and stable auxiliary material supply solutions, and promoting the overall efficiency improvement of the industry.
